Form 4: Azenta SVP Ginger Zhou Receives 13,042 RSU Grant

Azenta, Inc. disclosed that Ginger Zhou, SVP and GM of Multiomics, was granted 13,042 restricted stock units, a common form of executive compensation.

Summary

• Ginger Zhou, SVP and GM, Multiomics at Azenta, Inc. (AZTA), was granted 13,042 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this grant was November 24, 2025.
• No amount was paid upon the grant of these RSUs.
• The number of RSUs granted was determined by dividing a target award value by the average closing price of Azenta's common stock over the 20 trading days ending on the grant date.
• The RSUs are subject to time-based vesting, with 33-1/3% vesting per year, commencing on November 24, 2026.
• Following this transaction, Ginger Zhou beneficially owns 38,755 shares of common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation grant to a senior executive, which is a neutral to slightly positive event as it aligns management incentives with shareholder interests, but does not indicate significant operational or financial news.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the executive's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• RSUs serve as a retention mechanism, incentivizing the executive to remain with the company through the vesting period.

Negatives

• The RSUs have no immediate cash value and are subject to a multi-year vesting schedule, meaning the executive does not fully own them until future dates.
• The value of the compensation is subject to the future market price fluctuations of Azenta's common stock.

Risks

• Stock Price Volatility: The ultimate value of the RSUs to the executive is dependent on Azenta's stock price at the time of vesting, which can fluctuate.
• Forfeiture Risk: If the executive's employment terminates before the vesting dates, unvested RSUs will typically be forfeited.
• Dilution: The issuance of these shares upon vesting will result in a minor dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Future Outlook

The grant of Restricted Stock Units with a multi-year vesting schedule indicates a commitment to retaining key executives and aligns their long-term incentives with the company's performance. The future value of this compensation will depend on Azenta's stock performance.

Industry Context

The grant of Restricted Stock Units (RSUs) to a senior executive is a common and widely accepted practice in the biotechnology and life sciences tools industry, where Azenta operates. This form of equity compensation is used to attract, retain, and motivate key talent by linking their financial success to the long-term performance of the company's stock, similar to practices at peers like Danaher, Thermo Fisher Scientific, or Bio-Rad Laboratories.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across the life sciences and technology sectors, aligning with global benchmarks for executive incentive programs.
• The vesting schedule of 33-1/3% per year over three years is a common structure for time-based RSU grants, comparable to those observed at companies like Illumina, Agilent Technologies, or Sartorius AG, which aim to ensure executive retention and long-term commitment.
• The determination of RSU quantity based on a target award value divided by an average stock price over a period (20 trading days) is a typical methodology to smooth out short-term stock price volatility and ensure fairness in grant valuation, a practice seen in many publicly traded companies.

Related Party Transactions

• The grant of 13,042 Restricted Stock Units to Ginger Zhou, a Senior Vice President and General Manager, constitutes a transaction between the company and a key management personnel.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting, but also improved alignment of executive incentives with long-term shareholder value.
• Employees: Standard executive compensation practices can positively influence morale and retention of other key personnel.

Next Steps

• Vesting of 33-1/3% of the RSUs on November 24, 2026.
• Subsequent annual vesting of 33-1/3% of the RSUs on November 24, 2027, and November 24, 2028 (implied by '33-1/3% per year').

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a senior executive. While it aligns management incentives with shareholder interests, it does not present new material information regarding the company's operational performance, financial outlook, or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure for executive compensation.

Keywords

Azenta, AZTA, Restricted Stock Units, RSU Grant, Equity Compensation, Insider Transaction, Form 4, Executive Compensation, Ginger Zhou, Multiomics